Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Kyntra Bio, with a focus on how actual results compare to estimates impacting stock price [1] Earnings Expectations - Kyntra Bio is expected to report a quarterly loss of $3.89 per share, reflecting a year-over-year change of -94.5% [3] - Revenues are projected to be $1.6 million, down 49% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4] - A positive Earnings ESP of +24.07% suggests analysts have recently become more optimistic about Kyntra Bio's earnings prospects [11] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [9] - Kyntra Bio currently holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [11] Historical Performance - In the last reported quarter, Kyntra Bio was expected to post a loss of $4.01 per share but actually reported a loss of -$1.61, resulting in a surprise of +59.85% [12] - Over the past four quarters, Kyntra Bio has only beaten consensus EPS estimates once [13] Industry Comparison - Gossamer Bio, another player in the biomedical sector, is expected to report a loss of $0.19 per share, with revenues projected at $7.6 million, down 19% year-over-year [17] - Gossamer Bio's consensus EPS estimate has been revised 1.3% lower, resulting in a negative Earnings ESP of -30.21% [18]